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Abstract
Background: Celiac disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten. Gluten-
sensitive individuals (GS) cannot tolerate gluten and may develop gastrointestinal symptoms similar to those in CD,
but the overall clinical picture is generally less severe and is not accompanied by the concurrence of tissue
transglutaminase autoantibodies or autoimmune comorbidities. By studying and comparing mucosal expression of
genes associated with intestinal barrier function, as well as innate and adaptive immunity in CD compared with GS,
we sought to better understand the similarities and differences between these two gluten-associated disorders.
Methods: CD, GS and healthy, gluten-tolerant individuals were enrolled in this study. Intestinal permeability was
evaluated using a lactulose and mannitol probe, and mucosal biopsy specimens were collected to study the
expression of genes involved in barrier function and immunity.
Results: Unlike CD, GS is not associated with increased intestinal permeability. In fact, this was significantly reduced
in GS compared with controls (P = 0.0308), paralleled by significantly increased expression of claudin (CLDN) 4 (P =
0.0286). Relative to controls, adaptive immunity markers interleukin (IL)-6 (P = 0.0124) and IL-21 (P = 0.0572) were
expressed at higher levels in CD but not in GS, while expression of the innate immunity marker Toll-like receptor
(TLR) 2 was increased in GS but not in CD (P = 0.0295). Finally, expression of the T-regulatory cell marker FOXP3
was significantly reduced in GS relative to controls (P = 0.0325) and CD patients (P = 0.0293).
Conclusions: This study shows that the two gluten-associated disorders, CD and GS, are different clinical entities,
and it contributes to the characterization of GS as a condition associated with prevalent gluten-induced activation
of innate, rather than adaptive, immune responses in the absence of detectable changes in mucosal barrier
function.
Background
Gluten is the structural protein component of the grains
wheat, rye and barley, which are the basis for a variety
of flour- and wheat-derived food products consumed
throughout the world. Possibly, the introduction of glu-
ten-containing grains, which occurred about 10,000
years ago with the advent of agriculture, represented a
“mistake of evolution” that created the conditions for
human diseases related to gluten exposure, the best
known of which are mediated by the adaptive immune
system: wheat allergy and celiac disease (CD). In both
conditions, the reaction to gluten is mediated by T-cell
activation in the gastrointestinal mucosa. However, in
wheat allergy, it is the cross-linking of immunoglobulin
E (IgE) by repeat sequences in gluten peptides (for
example, Ser-Gln-Gln-Gln-(Gln-)Pro-Pro-Phe) that
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any medium, provided the original work is properly cited.triggers the release of chemical mediators, such as hista-
mine, from basophils and mast cells [1]. In contrast,
CD, which affects approximately 1% of the general
population, is an autoimmune disorder, as heralded by
the appreciation of specific serologic markers, most
notably serum antitissue transglutaminase (tTG) autoan-
tibodies, by the autoimmune enteropathy that charac-
terizes this condition and by autoimmune comorbidities.
Besides CD and wheat allergy, there are cases of glu-
ten reactions in which neither allergic nor autoimmune
mechanisms are involved. These are generally defined as
gluten sensitivity (GS) [2-5]. Some individuals who
experience distress when eating gluten-containing pro-
ducts and show improvement when following a gluten-
free diet may have GS instead of CD. GS patients are
unable to tolerate gluten and develop an adverse reac-
tion when eating gluten that usually, and differently
from CD, does not lead to small intestinal damage.
While the gastrointestinal symptoms in GS may resem-
ble those associated with CD, the overall clinical picture
is generally less severe and is not accompanied by the
concurrence of tTG autoantibodies or autoimmune dis-
ease. Typically, the diagnosis is made by exclusion, and
an elimination diet and “open challenge” (that is, the
monitored reintroduction of gluten-containing foods)
are most often used to evaluate whether the patient’s
health improves with the elimination or reduction of
gluten from the diet.
A number of in vitro studies have confirmed the cyto-
toxicity of gluten’s main antigen, gliadin. Gliadin has
agglutinating activity, reduces F-actin content, inhibits
cell growth, induces apoptosis, alters redox equilibrium
and causes a rearrangement of the cytoskeleton through
the zonulin pathway and the loss of tight junction (TJ)
competence in the gastrointestinal mucosa [6-9]. The
diversity of gluten-induced conditions is in line with the
notion that the immune system reacts to and deals with
the triggering environmental factor, gliadin, in distinct
ways. In the present study, we sought to gain initial
knowledge on intestinal barrier function and the
immune response to gluten in patients with GS. Specifi-
cally, we were interested in understanding to what
extent innate and adaptive immune pathways are acti-
vated in GS compared to CD. To achieve these aims, we
looked at the mucosal expression of genes associated
with intestinal barrier function and immune parameters
known or implied to be aberrantly regulated in CD. The
results provide the first documentation to date of genes
and pathways possibly involved in the pathogenesis of
GS, and, at the same time, contribute to improving our
understanding of the processes leading to CD and other
autoimmune phenomena.
Methods
Definition of GS
GS patients are defined as those patients in which CD,
wheat allergy and other clinically overlapping diseases
(type 1 diabetes, inflammatory bowel diseases and Heli-
cobacter pylori infection) have been ruled out and
whose symptoms were triggered by gluten exposure and
alleviated by gluten withdrawal. All enrolled patients
underwent a gluten challenge carried out for approxi-
mately 4 months under clinical supervision. At the end
of the challenge, patients underwent CD serology
screening, Human Leukocyte Antigen (HLA) DQ2/DQ8
typing and an upper endoscopy with duodenal biopsies.
Once endoscopies were performed, patients were placed
back on a gluten-free diet and their symptoms moni-
tored over time. GS were considered those patients with
negative autoantibody serology (endomysium antibodies-
immunoglobulin A (EMA-IgA) and tTG-IgA), normal
mucosa (Marsh stage 0) or increased intraepithelial lym-
phocytes (Marsh stage 1) and improvement of symp-
toms within days of the implementation of the diet. To
avoid any possible selection bias and to prove that these
patients are different from CD patients, we elected to
enroll every patient fulfilling the above-described defini-
tion of gluten sensitivity.
Subjects
Consent was obtained from all enrolled subjects after
the nature of the investigation was explained and in
accordance with the approved protocol from the Institu-
tional Review Board at the University of Naples. A total
of 26 GS patients diagnosed according to the criteria
outlined above were enrolled. For comparison, 42
patients with active CD were recruited according to the
modified 2004 criteria of the European Society of Pedia-
tric Gastroenterology, Hepatology and Nutrition (ESP-
GHAN) [10]. Finally, 39 control subjects were enrolled
from among individuals undergoing upper endoscopy
for dyspepsia. We limited our control group to indivi-
duals who had exclusively dyspeptic symptoms and no
underlying inflammation as proven by normal erythro-
cyte sedimentation rate, C-reactive protein and muco-
protein evaluation. These subjects did not have CD or
GS and are referred to hereinafter as dyspeptic controls
(DC).
Subject characteristics are summarized in Table 1. For
each set of experiments, a representative subgroup of
CD, GS and DC were analyzed on the basis of the sub-
jects’ consent to participate in part or all of the pro-
posed studies and on material transfer agreements
between the institutions involved in this project. At least
six duodenal biopsies were collected for histological
Sapone et al. BMC Medicine 2011, 9:23
http://www.biomedcentral.com/1741-7015/9/23
Page 2 of 11evaluation and gene expression. No selection bias based
on sex, age or type of symptoms was observed.
Determination of intestinal permeability
In vivo permeability was determined by means of the
lactulose/mannitol (LA/MA) test as previously described
[11]. The detection and measurement of the two sugar
probes in the urine was performed by high-performance
anion exchange chromatography coupled with pulsed
amperometric detection, which permits direct quantifi-
cation of nonderivative carbohydrates on a Dionex
model DX-500 with a gradient pump module GP40 and
sample loop of 50 μl. Samples were loaded onto Carbo-
P a cP A - 1 0 0g u a r dc o l u m n sa n de l u t e dw i t haN a O H -
NaAc gradient (Dionex, Sunnyvale, CA, USA).
Histology and immunohistochemistry of jejunal biopsies
Serial sections (4 μm) were prepared from duodenal for-
malin-fixed, paraffin-embedded biopsies. Biopsy
specimens were staged by histology according to the
Marsh classification [12,13]. Immunostaining to identify
intraepithelial lymphocytes (IELs) was performed as
described elsewhere [14]. Acetone-fixed sections (5 μm)
were stained with monoclonal antibodies for CD3
(1:200; Dako, Milan, Italy) and T-cell receptor gδ
(TCRgδ) (1:50; Thermo Scientific, Rockford, IL, USA)
using the peroxidase-antiperoxidase protocol. The sec-
tions were finally stained with Mayer’s hematoxylin
(Sigma-Aldrich, St. Louis, MO, USA). IEL density was
calculated as the percentage of enterocytes (ECs). All
slides were analyzed by two observers who were blinded
to these procedures.
Determination of mucosal gene expression
Intestinal gene expression was measured by quantitative
real-time polymerase chain reaction (qPCR) assay as
described previously [15]. Small intestinal biopsies from
participating subjects were homogenized and total RNA
Table 1 Clinical and laboratory characteristics of the study subjects
a
Characteristics DC CD GS
Number of samples 39 42 26
Age at diagnosis, yr
(mean ± SD)
33.36 ± 10.94 26.88 ± 11.77 30.73 ± 12.19
Sex (F/M) 23/16 32/10 17/9
Intestinal symptoms Dyspepsia Chronic diarrhea
Abdominal pain
Weight fluctuation
Weakness
Smelly, fatty stools
Diarrhea
Abdominal pain
Weight loss
Gas
Extraintestinal symptoms None Bone or joint pain
Osteoporosis
Behavioral changes
Tingling leg numbness
Muscle cramps
Missed menstruation
Infertility
Recurrent miscarriage
Delayed growth
Thyroiditis
Tooth discoloration
Unexplained anemia
Bone or joint pain
Osteoporosis
Leg numbness
Muscle cramps
Unexplained anemia
Glossitis
EMA-IgA All negative 34 positive
3 negative
5 not determined
All negative
tTG-IgA All negative 37 positive
5 negative
All negative
AGA-IgA/IgG All negative 29 positive
10 negative
3 not determined
12 positive
13 negative
1 not determined
MHC profile None determined 22 DQ2 and/or DQ8 positive
2 DQ2 and/or DQ8 negative
18 not determined
12 DQ2 and/or DQ8 positive
9 DQ2 and/or DQ8 negative
5 not determined
Wheat IgE 1 positive
37 negative
1 not determined
18 negative
24 not determined 22 negative
4 not determined
aDC, dyspeptic controls; CD, celiac disease; GS, gluten-sensitive individuals; SD, standard deviation; EMA-IgA, endomysium antibodies-immunoglobulin A; tTG-IgA,
tissue transglutaminase-immunoglobulin A; AGA-IgA/IgG, anti-gliadin antibodies-immunoglobulin A/immunoglobulin G; MHC, major histocompatibility complex;
IgE, immunoglobulin E.
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Island, NY, USA). Primers and probes for qPCR of spe-
cific transcripts and of the 18S gene as a housekeeping
control were purchased from Applied Biosystems (Foster
C i t y ,C A ,U S A ) .q P C Rw a sp e r f o r m e du s i n gt h eT a q -
Man protocol and the Applied Biosystems 7500 Fast
Real-Time PCR System. Amplification conditions were
as follows: 50°C for 2 minutes and 95°C for 10 minutes,
followed by 50 cycles at 95°C for 15 seconds and 60°C
for 1 minute. The data were calculated as the change in
cycle threshold (ΔCT) of the gene of interest to 18S and
are expressed as percentages of 18S (that is, 2
-ΔCT ×
100).
Statistical analysis
All data were analyzed and graphed using Prism version
5.0 software (GraphPad Software, La Jolla, CA, USA).
Most of the variables examined in this study appeared
to be arranged in a non-normal, positively skewed distri-
bution, making conventional parametric statistics mis-
leading. Therefore, data are described by the medians
and interquartile ranges (IQRs), and the degree of varia-
bility among groups was determined using the Kruskal-
Wallis nonparametric algorithm. A two-tailed Mann-
Whitney U test (MWU) was used for pairwise compari-
sons. The level of significance was set at P < 0.05.
Results
Clinical and laboratory characteristics of GS subjects
The patients who fulfilled the GS diagnostic criteria (see
Methods section) experienced symptoms overlapping
those presented by CD patients (see Table 1), but their
symptoms resolved within a few days after the imple-
mentation of the gluten-free diet, and they remained
symptom-free for the entire follow-up period (up to 4
years). Interestingly, 48% of GS patients were anti-glia-
din antibody (AGA)-positive, and 57% were HLA-DQ2-
positive and/or HLA-DQ8-positive. Fifty-six percent of
AGA-positive GS patients were HLA-DQ2-positive and/
or HLA-DQ8-positive, while the remaining 44% were
HLA-negative, suggesting that AGA production was not
associated with a HLA-DQ2-restricted and/or HLA-
DQ8-restricted presentation.
Intestinal permeability
While CD is consistently associated with impaired
mucosal barrier function and increased small intestinal
permeability, it is not known whether patients with GS
present similar alterations. To address this question, the
LA/MA urinary ratio was determined in the three study
groups. The LA/MA ratio, and hence small intestinal
permeability, varied significantly among the three groups
(P = 0.0113; Kruskal-Wallis test). In particular, it was
significantly higher in CD patients compared to GS
patients (P = 0.0138; MWU). A similar difference
between CD patients and DC only approximated signifi-
cance (P = 0.0950). Interestingly, the LA/MA ratio in
GS patients was also significantly reduced relative to DC
(P = 0.0308) (Figure 1).
Figure 1 shows that the increase in intestinal perme-
ability in CD patients, relative to DC, was ascribed to a
significantly increased urinary concentration of lactulose
(P = 0.0400), with no significant changes in mannitol
titers (P = 0.4937; not significant). Since the urinary
Figure 1 Reduced intestinal permeability in gluten-sensitive (GS) patients. Small intestinal permeability was probed by measuring the
urinary cumulative 5-hour amount of lactulose (LA) (percentage of ingested), mannitol (MA) and the LA-to-MA ratio as described in (see
Methods). Boxes represent the medians and interquartile ranges, and whiskers represent the range of independent determinations in 13 GS
patients, 11 celiac disease (CD) patients, and 14 dyspeptic controls (DC) (see intestinal permeability section of the text, pages 8-9). *P < 0.05
relative to DC and
†P < 0.05 relative to CD (Mann-Whitney U test).
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through the paracellular pathway, while mannitol is a
marker of the transcellular pathway [11], this confirms
that the changes in LA/MA ratio observed in CD reflect
increased paracellular permeability. Likewise, the
reduced LA/MA ratio in GS patients relative to CD and
DC appeared to be exclusively determined by reduced
lactulose titers, a finding again in line with the involve-
ment of processes regulating macromolecular passage
through the paracellular pathway. Specifically, the med-
ian percentage of urinary lactulose in GS was signifi-
cantly lower than that in CD (P = 0.0049), while the
difference between GS and DC was not significant (P =
0.1817; not significant).
Small intestinal expression of TJ proteins
To understand whether the changes in intestinal perme-
ability observed in CD and GS are associated with
altered expression of genes encoding for key TJ compo-
nents, the expression of claudins (CLDN), TJ protein
(TJP)-1 (also known as zonula occludens-1) and occlu-
din (OCLN) was determined in intestinal tissues
obtained by upper gastrointestinal endoscopy. Biopsy
specimens were immediately processed for mRNA
extraction, and the transcript levels of the genes
CLDN1, CLDN2, CLDN3, CLDN4, TJP1 and OCLN
were measured by qPCR. As shown in Figure 2, CLDN4
was expressed at significantly higher levels in GS than
in CD (P = 0.0286), while a similar difference with DC
almost reached significance (P = 0.0565). Similar levels
of CLDN4 were detected in biopsies from DC and CD
(P = 0.7279; not significant). Likewise, no significant
differences were observed across the three groups in the
mRNA levels of CLDN1 or CLDN2 or the other TJ-
related genes examined (not shown). Although this
might be due to the limited number of cases studied, it
is unlikely that inclusion of a larger sample would com-
pensate for the high level of variability and skewness
encountered within each group.
Intraepithelial lymphocytes
The GS patients recruited in this study did not present
relevant autoimmune phenomena and autoimmune ser-
ology (Table 1). In addition, in this group of patients,
we did not detect a clear-cut association with the major
histocompatibility complex (MHC) haplotype, as exten-
sively documented in CD patients. These clinical find-
ings led us to hypothesize that the adaptive immune
system may not be as critically involved in GS as it is in
CD (or in wheat allergy). To substantiate this argument,
our end points included markers of adaptive and innate
immune responses in the small intestinal mucosa of
these subjects. In a first series of observations, we com-
pared the numbers of IELs in GS versus CD patients. As
recently reported by our group [15], histology revealed a
normal to mildly inflamed mucosa (Marsh stage 0 or 1)
in GS patients, while all CD patients showed partial or
subtotal villous atrophy with crypt hyperplasia according
to the ESPGHAN criteria [10]. The results of CD3
immunohistochemistry are summarized in Figure 3. The
numbers of CD3
+ IELs varied considerably among the
three groups (P < 0.0001; Kruskal-Wallis test). As antici-
pated, CD patients had increased numbers of CD3
+ IEL
relative to DC (P < 0.0001; MWU). CD3
+ IELs were
Figure 2 The relative expression of tight junction (TJ)-related genes in the mucosa of gluten-sensitive patients (GS) versus celiac
disease patients (CD). Expression of the indicated genes encoding for components of the TJ complex was measured by quantitative
polymerase chain reaction assay of RNA extracted from small intestinal bioptic specimens (see Methods). Boxes represent the median
(interquartile ratio), and whiskers represent the range of relative RNA levels, expressed as a percentage of an 18S housekeeping gene in 24 GS
patients, 31 CD patients and 24 dyspeptic controls. *P < 0.05 relative to CD (Mann-Whitney U test).
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(P < 0.0001), but significantly less so than in CD (P =
0.0012). Notably, though, all but four GS patients had
IEL numbers above the currently accepted range of nor-
mality (≤30/100 EC), suggesting an intermediate-level,
yet pathogenetically significant, involvement of the adap-
tive immune system in this condition. On the other
hand, the number of TCRgδ IELs was consistently ele-
v a t e di nC D( > 3 . 4 / 1 0 0E C s ) ,w h i l et h en u m b e r si nG S
and DC were similar (data not shown).
Mucosal expression of adaptive immunity-related
cytokines
A number of studies have documented the gluten-depen-
dent rise in the systemic and mucosal expression of cyto-
kines associated with Th1 and Th17 adaptive responses
in CD [16-19]. We have recently shown that the Th17
signature cytokine, IL-17A, is expressed at significantly
higher levels in the small intestinal mucosa of CD
patients but not GS patients [15]. We have also shown
that gliadin induces circulating monocytes to produce
the Th17-active cytokine, IL-23, an effect mediated by
concomitant expression of IL-1b and IL-6 [17,20]. To
extend these observations and to further define the role
of adaptive immunity in GS, mRNA extracted from small
intestine biopsies was subjected to qPCR for expression
of the pleiotropic, Th17-activating cytokine interleukin
(IL)-6, the Th1 cytokine interferon (IFN)-g, and IL-21, a
Th1 cytokine involved both in the differentiation of Th17
cells and in sustaining ongoing Th1 responses [21].
A ss h o w ni nF i g u r e4 ,C Dp a t i e n t sa sag r o u p
expressed higher levels of transcripts for IL-6 (IL6),
IFN-g (IFNG) and IL-21 (IL21) relative to DC. However,
because of a high degree of variability among CD
donors and because of a subgroup effect already docu-
mented in our earlier report on IL-17A [15], only the
difference in IL-6 expression was statistically significant
(P = 0.0124), while the differences in IFNG and IL21
transcript levels approximated significance (P = 0.0700
and P = 0.0572, respectively). Levels of IL6, IFNG,a n d
IL21 transcripts in specimens from GS patients did not
differ significantly from those in DC or CD, except for a
significant reduction in IFNG levels relative to CD (P =
0.0222). IFNG was the only cytokine gene tested that
showed a significant degree of variability across the
three groups (P < 0.0428; Kruskal-Wallis test). Thus, in
line with its role in Th17 cell differentiation, IL-6 is
expressed at significantly increased levels in CD mucosa,
but not in GS mucosa. A concomitantly reduced expres-
sion of IFN-g in GS relative to CD supports the notion
of a lower-level involvement of the adaptive immune
system in this condition.
Small intestinal expression of Toll-like receptors
It has been reported that the expression of Toll-like
receptor 1 (TLR1), TLR2,a n dTLR4 is increased in the
small intestine mucosa of CD patients, lending support
to the idea that innate immune phenomena may precede
and/or accompany the progression of CD and other
autoimmune conditions [22-24]. To preliminarily assess
the involvement of innate immunity in GS, we com-
pared the expression of these molecules in fresh biopsies
from the three study groups. As illustrated in Figure 5,
expression of TLR1 and TLR2,b u tn o tTLR4,m R N A
w a sh i g h e ri nC Dp a t i e n t st h a ni nD C ,b u tn e i t h e ro f
these differences reached significance. In contrast, rela-
tive to DC, patients with GS presented significantly
higher levels of TLR2 transcripts (P = 0.0295), while
transcript levels of TLR1 and TLR4 in GS were generally
higher without reaching significance (P =0 . 0 9 3 2a n dP
= 0.1274, respectively).
Mucosal expression of regulatory T-cell-associated genes
To preliminarily assess whether a difference in immune
regulatory function may account for the differential
involvement of the adaptive system in CD versus GS
patients, we measured mRNA expression of two regula-
tory T-cell (Treg) signature molecules, forkhead box P3
(FOXP3) and transforming growth factor-b1 (TGFB1), in
small intestinal biopsy specimens. In contrast to earlier
reports [25,26], the levels of expression of both FOXP3
and TGFB1 in CD patients did not differ significantly
from those in DC (P =0 . 8 8 6 8a n dP = 0.1535, respec-
tively). As for TGFB1, there appeared to be a trend
Figure 3 Reduced numbers of intraepithelial lymphocytes
(IELs) in gluten-sensitive patients (GS) versus celiac disease
patients (CD). Small intestinal bioptic specimens were stained for
the T-cell marker CD3 in immunohistochemistry, and CD3
+ cells are
enumerated as indicated in Methods. Boxes represent the median
(interquartile range), and whiskers represent the range of IEL
numbers relative to 100 enterocytes in the same samples in 16 GS,
11 CD and 12 dyspeptic controls (DC). ***P < 0.0005 relative to DC;
†††P < 0.0005 relative to CD (Mann-Whitney U test).
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CD patients (Figure 6). This phenomenon was more
accentuated in GS patients, in whom expression of
FOXP3 and TGFB1 was, significantly for FOXP3,
reduced relative to DC (P = 0.0325 and P = 0.0710,
respectively). FOXP3 reduction in GS accounted for a
significant variation across groups (P < 0.0250; Kruskal-
Wallis test) and was also significant relative to CD (P =
0.0293), while no significant difference was observed in
TGFB1 expression in GS versus CD patients (P =
0.7832). These findings, quite opposite to our starting
hypothesis but perhaps in line with earlier reports on
CD and other conditions [27,28], may suggest a reduced
level of activation and/or recruitment of Treg cells in
the GS small intestine mucosa relative to gluten-tolerant
controls.
Discussion
CD, an autoimmune enteropathy, results from an inap-
propriate T-cell-mediated adaptive immune response
against ingested gliadin. In the past few years, though, it
has become apparent that “classic” CD represents the
tip of the iceberg of an overall disease burden [4,29]. An
emerging problem is the clinical characterization of a
Figure 4 Increased levels of transcripts for effector cytokines in the mucosa from celiac disease patients (CD) but not gluten-sensitive
patients (GS). Expression of the indicated genes was measured by quantitative polymerase chain reaction assay (see Methods). Boxes represent
the median (interquartile range) and whiskers represent the range of RNA levels relative to an 18S housekeeping gene in 13 GS, 19 CD and 11
dyspeptic controls (DC). *P < 0.05 relative to DC (Mann-Whitney U test).
Figure 5 Increased levels of transcripts for pattern recognition receptors in the mucosa from gluten-sensitive patients (GS) but not
celiac disease patients (CD). Expression of the indicated genes encoding for Toll-like receptors TLR1, TLR2 and TLR4 was measured by
quantitative polymerase chain reaction assay (see Methods). Boxes represent the median (interquartile range) and whiskers represent the range
of RNA levels relative to an 18S housekeeping gene in 8 GS, 12 CD and 5 dyspeptic controls (DC). *P < 0.05 relative to DC (Mann-Whitney U
test).
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10% of the general population, presenting with symp-
toms similar to CD but with negative CD serology and
histopathology. As in CD, these patients, here and else-
where referred to as GS [15], experience distress when
eating gluten-containing products and show improve-
ment when following a gluten-free diet. Differently from
CD, though, in GS the adverse reactions that develop
while eating gluten are not followed by the appearance
of autoantibodies and by persisting damage to the small
intestine. Symptoms in GS may resemble some of the
gastrointestinal symptoms that are associated with CD
or wheat allergy, but objective diagnostic tests for this
condition are currently missing. Therefore, a diagnosis
of GS is commonly made by exclusion.
In itself, the absence of autoantibodies and intestinal
lesions does not rule out the intrinsic toxicity of gluten,
whose intake, even in non-CD individuals, has been asso-
ciated with damage to other tissues, organs and systems
besides the intestine [6,30,31]. In the present study, we
have sought to identify functional, morphologic and
immunologic parameters to help differentiate GS from CD
and to preliminarily understand its pathophysiology. We
report here for the first time evidence of differential intest-
inal mucosal responses to gluten in these two conditions.
We have shown that a normal to mild histology in GS
is paralleled by a conserved barrier function. Indeed,
small intestinal permeability, when tested with a LA/MA
double sugar probe, was significantly lower in GS than
in CD patients or even DC. Increased intestinal perme-
ability is thought to be an early biological change that
precedes the onset of several autoimmune diseases
[32-34]. Loss of intestinal barrier function brings with it
a continuous aberrant passage of antigens across the
intestinal epithelium. This may cause a switch from tol-
erance to immunity, hence representing an increased
risk for autoimmune and allergic diseases in individuals
whose other genetic determinants, MHC and non-MHC,
give rise to inappropriate antigen processing and presen-
tation. In the intestinal epithelium, paracellular perme-
ability is regulated by intercellular TJ proteins. As
recently shown, CLDNs are integral TJ components that
are critical for maintaining cell-cell adhesion in epithe-
lial monolayers [35-37]. The overall balance of CLDN
species expressed in a particular cell type help to define
the characteristics of its TJ. For instance, CLDN1 and
CLDN4 are postulated to decrease, whereas CLDN2 is
postulated to increase TJ-dependent permeability [35].
In line with this notion, and with the appreciation of
reduced small intestinal permeability in GS patients, we
have shown here that the GS mucosa expresses signifi-
cantly higher levels of transcripts for CLDN4 relative to
CD or DC. In contrast, other CLDN genes and other
genes associated with TJ function measured in this
study did not appear to be expressed differently in the
GS or CD mucosa compared to controls. Together,
these findings suggest that the distinct clinical and sero-
logical features between GS and CD patients are
Figure 6 Reduced levels of transcripts of immune regulatory genes in the mucosa from gluten-sensitive patients (GS), but not celiac
disease patients (CD). Expression of the indicated genes was measured by quantitative polymerase chain reaction assay (see Methods). Boxes
represent the median (interquartile range) and whiskers represent the range of RNA levels relative to an 18S housekeeping gene in 19 GS, 12 CD
and 8 dyspeptic controls (DC). *P < 0.05 relative to DC (Mann-Whitney U test).
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function and with apparent differences in the expression
of CLDN4, which encodes for a critical TJ component
[38]. Further studies are required to compare the distri-
bution and assembly of this and other TJ proteins in
these conditions.
Patients with GS do not present significant autoim-
mune or allergic comorbidities, and, as we also have
shown here, the serology for common autoantibodies,
including anti-tTG IgA, is negative. Interestingly, AGA
IgA and IgG were positive in almost 50% of cases. Simi-
larly, higher than expected titers of AGAs, signs and
symptoms associated with non-CD gluten sensitivity,
have also been reported for schizophrenia [39] and aut-
ism spectrum disorders [40]. While in CD there is a
strong genetic association with the class II MHC haplo-
type, with about 95% of patients carrying HLA-DQ2 and
the remaining 5% carrying HLA-DQ8,w eh a v es h o w n
that only about 50% of patients with GS carry HLA-
DQ2 and/or HLA-DQ8, a percentage slightly higher than
that in the general population. This suggests a reduced
level of involvement of MHC-dependent adaptive
immune responses in GS relative to CD. We have
further shown that the GS mucosa contains increased
numbers of CD3
+ IELs, even though these numbers
were significantly lower than those in active CD patients
in the context of relatively conserved villous architec-
ture, corresponding to the 0 and 1 stages of the Marsh
classification. This is in line with a more limited involve-
ment of the adaptive immune system in GS and may
explain why this condition is not accompanied by signif-
icant autoimmune phenomena.
In CD, an adaptive response has been shown to be
triggered by tTG-deamidated gluten peptides bound to
D Q 2o rD Q 8 .T h i si n v o l v e st h em u c o s a lr e c r u i t m e n t
and activation of Th1 and Th17 clones and the produc-
tion of Th1- and Th17-associated cytokines, namely,
IFN-g and IL-17A, which contribute to disrupting bar-
rier function and initiating tissue damage [16,18-21,41].
In an earlier report, we showed that IL-17A transcripts
are expressed at significantly higher levels in the small
intestine mucosa of at least a subgroup of CD patients,
but not in GS patients [15]. In this study, we have
extended this finding and show that the Th1 signature
cytokine, IFN-g, also is expressed at significantly lower
levels in the GS versus CD mucosa. Moreover, in CD
but not in GS, we observed a significantly enhanced
expression of IL-6, a pleiotropic cytokine that is known
to promote the differentiation and function of Th17
cells, as well as a similar trend in the expression of IL-
21, consistent with its established role in the pathophy-
siology of Th1 and Th17 cells.
These findings might indicate that GS is an inflamma-
tory condition mostly supported by innate immune
mechanisms. Among these, TLRs represent a family of
evolutionarily conserved receptors able to detect micro-
bial invasion via pattern recognition and mediate a rapid
inflammatory response which may or may not progress
into an antigen-dependent adaptive response. Different
combinations of TLRs are expressed in hematopoietic
cells and nonhematopoietic c e l l ss u c ha si n t e s t i n a l
epithelial cells [42-44]. In this study, we have observed
that small intestine expression of TLR2, and to a lesser
extent TLR1 but not TLR4, is increased in GS patients.
In the absence of markers of adaptive immunity, as we
have seen, this suggests a prevalent role of the innate
immune system in the pathogenesis of GS.
T a k e nt o g e t h e r ,t h e s ef i n d i n g ss u p p o r tt h ei d e at h a t
the prevalent involvement of innate versus adaptive
immune pathways may help explain the clinical and ser-
ological differences in GS versus CD patients. Reduced
function of Treg cells, and specifically of “adaptive” Treg
cells, has been proposed to account for the loss of
immune homeostasis and the development of autoim-
mune responses in CD and related conditions [26]. It
might be inferred, then, that Treg could efficiently pre-
vent progression to this response in GS patients. A sig-
nificantly reduced mucosal expression of the distinctive
Treg marker, FOXP3, as appreciated in GS patients in
this study, is therefore surprising and counterintuitive in
the light of these considerations. However, at least as
surprisingly, in several studies FOXP3 and other Treg-
expressed molecules, such as TGFB1, have been found
to be upregulated in the peripheral blood and intestinal
mucosa of patients with CD and related conditions, for
example, type 1 diabetes [28,45]. Analogous findings
have been reported in other conditions associated with
the extensive involvement of adaptive immunity, such as
allergy and asthma, leading to speculation that a com-
pensatory expansion and/or mobilization of Treg might
take place concomitantly with the buildup of an adap-
tive effector response [46]. Paradoxically, then, if this
assumption is true, a reduced expression of Treg mar-
kers in GS might be interpreted in the context of a gen-
erally reduced activation of adaptive immunity relative
to CD. While more studies obviously are needed to elu-
cidate this issue, a better understanding of Treg function
in CD and related conditions will help characterize the
possible pathogenetic role of reduced Treg activation
and/or recruitment in GS.
Conclusions
The results of this study suggest that CD and GS are dis-
tinct clinical entities caused by different intestinal muco-
sal responses to gluten. CD results from a complex, and
as yet undetermined, interplay of increased intestinal per-
meability, mucosal damage, environmental factors in
addition to gluten, and genetic predisposition, which
Sapone et al. BMC Medicine 2011, 9:23
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Page 9 of 11involves both MHC and non-MHC genes. The typical
intestinal lesions in CD are thought to be mediated by
both innate and adaptive immune effector pathways. Our
findings suggest that, in a different way, GS is associated
with prevalent activation of an innate immune response.
Although the mechanisms responsible for the loss of
intestinal barrier function in CD have been delineated in
part, the factors responsible for the loss of gluten toler-
ance and the development of autoimmunity in this condi-
tion are still incompletely understood. We believe that
this study could contribute to the clinical characteriza-
tion of GS as a condition associated with prevalent glu-
ten-induced activation of innate immunity in the absence
of detectable changes in mucosal barrier function, and
that it provides additional clues to the definition of the
complex gluten-induced changes in TJ regulation and
immune processes underlying CD pathogenesis. Double-
blind, placebo-controlled studies are necessary to further
solidify the definition of GS patients and to search for
specific biomarkers for a proper diagnosis.
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